| Dr Silke A Bernert, MD | |
|
2802 Papermill Rd, Reading, PA 19610-1065 | |
| (484) 628-2571 | |
| Not Available |
| Full Name | Dr Silke A Bernert |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 25 Years |
| Location | 2802 Papermill Rd, Reading, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215195912 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tower Health At Home - Berks | Wyomissing, PA | Home health agency |
| Reading Hospital | West reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tower Health Medical Group | 7618889213 | 577 |
News Archive
Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.
Two universities are eyeing the chance to be the first to build a medical school in one of the few states without one. The jockeying of the two schools — one a nonprofit, the other for-profit — to open campuses in Montana highlights the rapid spread of for-profit medical learning centers despite their once-blemished reputation.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.
World Congress of Cardiology Report - Although elderly AF patients are at much higher risk for stroke, they are undertreated for stroke prophylaxis compared to younger patients.
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.
› Verified 9 days ago
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.
Two universities are eyeing the chance to be the first to build a medical school in one of the few states without one. The jockeying of the two schools — one a nonprofit, the other for-profit — to open campuses in Montana highlights the rapid spread of for-profit medical learning centers despite their once-blemished reputation.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.
World Congress of Cardiology Report - Although elderly AF patients are at much higher risk for stroke, they are undertreated for stroke prophylaxis compared to younger patients.
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Silke A Bernert, MD 2802 Papermill Rd, Reading, PA 19610-1065 Ph: (484) 628-2571 | Dr Silke A Bernert, MD 2802 Papermill Rd, Reading, PA 19610-1065 Ph: (484) 628-2571 |
News Archive
Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.
Two universities are eyeing the chance to be the first to build a medical school in one of the few states without one. The jockeying of the two schools — one a nonprofit, the other for-profit — to open campuses in Montana highlights the rapid spread of for-profit medical learning centers despite their once-blemished reputation.
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.
World Congress of Cardiology Report - Although elderly AF patients are at much higher risk for stroke, they are undertreated for stroke prophylaxis compared to younger patients.
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.
› Verified 9 days ago
Mark Walsh, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1623 Morgantown Rd, Reading, PA 19607 Phone: 272-228-0476 | |
Dr. Patti Jo Brown, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1623 Morgantown Road, Reading, PA 19607 Phone: 610-796-6354 Fax: 610-796-6470 | |
Robyn Kay Gansner, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1623 Morgantown Rd, Reading, PA 19607 Phone: 610-796-6354 Fax: 610-796-6470 | |
Dr. Barbara Ann Hoffer, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1623 Morgantown Rd, Reading, PA 19607 Phone: 610-796-6354 Fax: 610-796-6470 | |
Dr. Kristy Marie Kozlek, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1623 Morgantown Rd, Reading, PA 19607 Phone: 610-796-6364 Fax: 610-796-6470 |